Skip to main content
SpringerLink
Log in

Measuring disease specific quality of life in localized prostate cancer: The Dutch experience

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Objective: We aimed at developing and testing a Dutch health-related quality of life measure for localized prostate cancer patients. Methods: Scales on urinary and bowel function and bother from the UCLA Prostate Cancer Index (PCI) underwent formal linguistic and cultural translation. PCI sexual scales were replaced by an existing Dutch sexual activities module (SAc). After qualitative pilot testing 389 patients with localized prostate cancer (mean age 67 ± 7 years) completed the measure before and at 2 time points after primary treatment. Psychometric properties (feasibility, score distribution, reliability, construct validity and responsiveness to change) of the new instrument were analyzed. Results: Response rates ranged from 93% at baseline to 87% after treatment. Urinary and bowel function scales showed Cronbach's αs >0.7. Urinary function and bother, and bowel function and bother were significantly correlated. Pre- vs. post-prostatectomy effect sizes were >0.9 only for urinary scales; while pre- vs. post-radiotherapy effect sizes were >0.75 only for bowel scales. Six months after baseline erectile dysfunction was reported by 64% of respondents, either as a problem in sexual activity or as a reason for not being sexually active. Conclusion: The Dutch PCI and SAc performed well in men treated for early stage prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19(6): 1619–1628.

    Google Scholar 

  2. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 2001; 46(2): 87–97.

    Google Scholar 

  3. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97(2): 237–244.

    Google Scholar 

  4. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: Aresponse. Qual Life Res 2001; 10(5): 405–413; discussion 415-420.

    Google Scholar 

  5. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095–1108.

    Google Scholar 

  6. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36(7): 1002–1012.

    Google Scholar 

  7. Slob AK, Blom JH, van der Werff ten Bosch JJ. Erection problems in medical practice: Differential diagnosis with relatively simple method. J Urol 1990; 143(1): 46–50.

    Google Scholar 

  8. Incrocci L, Madalinska JB, Essink-Bot ML, Van Putten WL, Koper PC, Schroder FH. Sexual functioning in patients with localized prostate cancer awaiting treatment. J Sex Marital Ther 2001; 27(4): 353–363.

    Google Scholar 

  9. Staquet MJ, Hays RD, Fayers PM. Quality of Life Assessment in Clinical Trials, Methods and Practice. Oxford University Press, 1998.

  10. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press, 1977.

    Google Scholar 

  11. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49(6): 822–830.

    Google Scholar 

  12. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56(6): 899–905.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    I.J. Korfage, M.-L. Essink-Bot, J.B. Madalinska & H.J. de Koning

  2. Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    W.J. Kirkels

  3. Department of Urology and Health Services, UCLA Schools of Medicine and Public Health, Los Angeles, CA, USA

    M.S. Litwin

Authors
  1. I.J. Korfage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M.-L. Essink-Bot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.B. Madalinska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W.J. Kirkels
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M.S. Litwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H.J. de Koning
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korfage, I., Essink-Bot, ML., Madalinska, J. et al. Measuring disease specific quality of life in localized prostate cancer: The Dutch experience. Qual Life Res 12, 459–464 (2003). https://doi.org/10.1023/A:1023402706666

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023402706666

Search

Navigation